the aid library

LIST OPTIONS

Filter

2533

Strengthening COVID-19 vaccine demand and uptake in refugees and migrants

World Health Organization WHO (2022) C_WHO

an operational guide to support all those responsible for planning and implementing the rollout of COVID-19 vaccine to refugees and migrants at national and local levels, 14 March 2022

Repensando a saúde com a presença da Covid-19 - Lições e Desafios

Ministerio da Saude, CONASS, Conasems et al. Ministerio da Saude Brasil (2021) C1

Rethinking Health with Covid-19 Lessons and Challenges Este e-book que integra estratégias de três Projetos PROADISUS (Lean nas Emergências, Reab pós-COVID-19 e Cuidados Paliativos) e expõe temas relevantes, relacionados à necessidade de retorno seguro de atividades hospitalares, em paralelo ... more

Guidance for the prevention and control of COVID-19 in temporary reception centres in the context of the large numbers of people fleeing Ukraine
recommended

European Centre for Disease Prevention and Control ECDC (2022) C1

This document offers public health guidance for the prevention and control of COVID-19 in reception centres, and other temporary accommodation facilities, in the context of the mass influx of Ukrainian people into the European Union (EU), the European Economic Area (EEA) and the Republic of Moldova.

External Link

Operational guidance on establishing an ultra-cold chain system in support of the Pfizer-BioNTech COVID-19 vaccine rollout, 1 February 2022

World Health Organization WHO (2022) C_WHO

Available in different languages

El impacto de la pandemia de COVID-19 en la salud mental de los trabajadores de la salud en Chile: datos iniciales de The Health Care Workers Study

Alvarado R., Ramírez J. et al (2021) C2

Background: Healthcare workers’ mental health was affected by SARS-CoV-2 pandemic. Aim: To evaluate healthcare workers’ mental health and its associated factors during the pandemic in Chile. Material and Methods: An online self-reported questionnaire was designed including the Goldberg Healt... more

External Link

The successful COVID-19 vaccine rollout in Chile: Factors and challenges

Castillo C., Villalobos Dintrans P. et al (2021) C2

The aim of this article is to identify the elements behind the country’s successful COVID-19 rollout as well as lessons and chal lenges derived from this process. The analysis is relevant to many countries today—as they keep searching for strategies to cope with the second year of the COVID-19 p... more

Recomendaciones provisionales para el uso de la vacuna BBV152 COVAXIN® de Bharat Biotech contra la COVID-19: orientaciones provisionales, primera publicación: 3 de noviembre de 2021, actualización: 15

Organización Mundial de la Salud OMS (2022) C_WHO

Informe Impacto de La Pandemia COVID-19 en las Enfermedades no Transmisibles en Chile 2022

Ministerio de Salud, Gobierno de Chile (2022) C1

Informe

Download (207)

View PDF (233)

Learning About Meaningful Engagement with Organizations of Persons with Disabilities in Public Health Emergencies, Including COVID-19

UN Children's Fund UNICEF (2022) C_UNICEF

This report presents the findings from a ‘deep dive’ undertaken by UNICEF East Asia and the Pacific Regional Office to consider the experiences in Cambodia, Indonesia, the Lao People’s Democratic Republic, Malaysia, Myanmar, the Philippines and the Pacific. The target audience for this report ... more

Download (137)

View PDF (325)

Update 80: What we know about new COVID-19 Variants of Concern - the latest on the global situation & Omicron BA.4/5

World Health Organization WHO (2022) C_WHO

While COVID-19 virus continues to circulate and evolve, new variants are constantly emerging. Most of the current COVID-19 cases are driven by the circulation of the BA.5 subvariant of Omicron. The COVID-19 vaccines are being updated with Omicron variants to provide broader immunity against circulat... more

Note d’orientation de l’OMS : Prise en charge clinique de la COVID-19

Organisation mondiale de la santé (OMS) (2022) C_WHO

Les notes d’orientation décrivent les mesures essentielles que les décideurs nationaux et infranationaux peuvent mettre en place concernant les aspects suivants de la lutte contre la COVID-19 : les tests de diagnostic, la prise en charge clinique, la réalisation des cibles en matière de vaccin... more

Note d’orientation de l’OMS : tests de diagnostic de la COVID-19

Organisation Mondiale de la Santé OMS (2022) C_WHO

Les notes d’orientation exposent les mesures essentielles que les décideurs peuvent mettre en œuvre aux niveaux national et infranational pour les éléments suivants : tests de diagnostic de la COVID-19, prise en charge clinique de la COVID-19, atteinte des cibles en matière de vaccination con... more

Risk communication and community engagement: a compendium of case studies in times of COVID-19

World Health Organization WHO, Regional Office of Europe (2022) C_WHO

This collection of case studies on risk communication and community engagement (‎RCCE)‎ from 18 different country/area level public health partners in the WHO European Region provides evidence of numerous results achieved and lessons learned since the start of the COVID-19 pandemic. RCCE has not... more

Download (228)

View PDF (264)

Gender based violence and sexual and reproductive health during the Covid-19 pandemic in the pacific region

United Nations Population Fund UNFPA (2022) C1

Sexual and reproductive health is health issues that have to do with your body, sex, relationships, and having and giving birth to children. This includes having the information you need to be able to make your own decisions about your body, when to have sex, and whether or not to become a parent. T... more

Download (143)

View PDF (215)

Africaʼs response to the COVID-19 pandemic. A summary of country reports

World Health Organization WHO, Regional Office of Africa (2022) C_WHO

January 2020 to December 2021

Download (124)

View PDF (163)

Weekly epidemiological update on COVID-19 - 4 January 2023

World Health Organization WHO (2023) C_WHO

Globally, more than 3 million new cases and 10 000 deaths have been reported in the week of 26 December 2022 to 1 January 2023. This represents a reduction in weekly cases and deaths of 22% and 12%, respectively. In the last 28 days (5 December 2022 to 1 January 2023), over 14.5 million cases and ov... more

Download (185)

View PDF (361)

Écart de rémunération entre femmes et hommes dans le secteur de la santé et des soins : une analyse de la situation dans le monde à l’ère de la COVID-19

World Health Organisation (WHO) (2022) C_WHO

Le secteur de la santé et des soins constitue une source d’emploi considérable dans le monde, en particulier pour les femmes. Les personnels de santé et d’aide à la personne représentent environ 3,4 % de la population active mondiale, notamment quelque 10 % dans les pays à revenu élevé e... more

Download (200)

View PDF (247)

Modelling COVID-19 vaccination status and adherence to public health and social measures, Eastern Mediterranean Region and Algeria

World Health Organisation (WHO) (2023) C_WHO

The introduction of vaccines for coronavirus disease 2019 (COVID-19) added another measure to the existing set of recommended preventive measures (wearing a mask in public, keeping a distance from other people and regular handwashing). The roll-out of the vaccines, however, raised concerns that vac... more

Download (137)

View PDF (169)

Inclusión de las personas mayores en la planificación para emergencias: Perspectivas durante y después de la pandemia de COVID-19

World Health Organisation (WHO) (2023) C_WHO

En la Región de las Américas, las poblaciones están envejeciendo y se está experimentando una rápida transición demográfica. El índice de envejecimiento, que refleja el tamaño de los grupos de mayor edad por 100 en comparación con los menores de 15 años, demuestra claramente el aumento de... more

Download (285)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Guidance for the prevention and control of COVID-19 in temporary reception centres in the context of the large numbers of people fleeing Ukraine recommended

Guidance for the prevention and control of COVID-19 in temporary reception centres in the context of the large numbers of people fleeing Ukraine
recommended